QuantaMatrix is a renowned brand and a leader in the field of microbiology and molecular diagnostics. Established in 2010, QuantaMatrix specializes in in-vitro diagnostics and was founded as a spin-off from Biophotonics and Nano Engineering Lab (BiNEL) at Seoul National University, led by Dr. Sunghoon Kwon.

One of QuantaMatrix's primary offerings is their Rapid Antimicrobial Susceptibility Testing (dRAST TM) solution, which plays a crucial role in combating sepsis. Sepsis is a life-threatening condition with a mortality rate of over 40%, and timely treatment is crucial. QuantaMatrix's dRAST TM solution significantly reduces the time to optimal treatment, saving 30-50 hours compared to conventional methods.

In addition to sepsis, QuantaMatrix offers other innovative solutions, including the QDST TM for rapid drug susceptibility testing of Mycobacterium tuberculosis, the QPLEX TM Alz plus assay for early detection of Alzheimer's disease, and the Quanti9 TM & QuantiGal TM prognostic prediction kit for cardiovascular diseases. QuantaMatrix's mission is to improve patient health, reduce healthcare costs, and combat antimicrobial resistance. With their cutting-edge technology and commitment to innovation, QuantaMatrix strives to be at the forefront of in-vitro diagnostics in the fields of microbiology, molecular biology, and immunoassay